Hideki Nagao Acquires Shares of MediciNova, Inc.
Nagao bought 44,500 shares of MediciNova on June 23, 2026.
Key Points
- Hideki Nagao purchased 44,500 shares of MediciNova, Inc. (MNOV) on June 23, 2026.
- MediciNova shares traded near $1.31 on Friday, with a market cap of about $64.5 million.
- Analysts maintain a positive outlook on MNOV, with several 'buy' ratings and targets up to $11.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Hideki Nagao recently bought 44,500 shares of MediciNova, Inc. (NasdaqGM: MNOV) on June 23, 2026. The shares were acquired without a specified price, reflecting a strategic move in his investment portfolio.
Other Institutional Activity in MediciNova
Institutional investors have shown varied interest in MediciNova. For instance, Essex Woodlands Management, Inc. held steady with 1,105,941 shares valued at about $1.52 million. BlackRock, Inc. added 984 shares, ending with 705,954 shares worth approximately $967,157, marking a slight 0.1% increase. Vanguard Capital Management LLC opened a new position with 611,039 shares valued at $837,123. Geode Capital Management, LLC increased its holdings by 14,260 shares, totaling 543,843 shares with a value of $745,254, representing a 2.7% increase.
MediciNova, Inc. Stock Down 8.7%
Shares of MediciNova (NasdaqGM: MNOV) traded near $1.31 on Friday. The company has a market capitalization of approximately $64.5 million. MediciNova's forward P/E ratio is not meaningful as it is not currently profitable. The stock has experienced a 52-week low of $1.17 and a high of $1.96, with a 50-day moving average of $1.36 and a 200-day moving average of $1.41. The current ratio stands at 9.09, indicating strong liquidity, and the debt-to-equity ratio is 0.42.
$MNOV stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at MediciNova, Inc.
Alongside Hideki Nagao, other insiders also bought shares on June 23, 2026. Carolyn Beaver and Nicole Lemerond each purchased 44,500 shares. Earlier in the year, on January 16, 2026, Chief Medical Officer Kazuko Matsuda and President and CEO Yuichi Iwaki each acquired 350,000 and 450,000 shares, respectively.
Analysts Set New Price Targets
Analysts maintain a positive outlook on MediciNova. On May 4, 2026, D. Boral Capital maintained its 'buy' rating with a $9.00 price target. Maxim Group reinstated a 'buy' rating with a $6.00 target on March 23, 2026, while HC Wainwright & Co. initiated coverage with a 'buy' rating and a $10.00 target on March 16, 2026. The consensus target price stands at $9.00, based on three analyst opinions.
About MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company based in La Jolla, California, focusing on developing treatments for serious diseases with unmet medical needs. The company is advancing MN-166 (ibudilast) for neurological disorders like multiple sclerosis and glioblastoma, and MN-001 (tipelukast) for fibrotic diseases. Led by CEO Dr. Yuichi Iwaki, MediciNova operates in the biotechnology sector with a small team of six employees.
Bottom Line
MediciNova continues to attract attention from insiders and institutional investors alike. While the company is not currently profitable, its ongoing research in unmet medical needs keeps it on analysts' radar with positive ratings. Investors should remember that insider transactions and institutional activities are based on past data and may not reflect current positions.
Get MediciNova, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MNOV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.